Brief: Antengene Says China Nmpa Approved A Phase Ii Open-Label Study Of Compound Atg-016 In Patients
30/03/2022 02:41
March 30 (Reuters) - Antengene Corporation Ltd 6996.HK :
* CHINA NMPA APPROVED A PHASE II OPEN-LABEL STUDY OF
COMPOUND
ATG-016 IN PATIENTS WITH HIGH-RISK MYELODYSPLASTIC SYNDROMES
Further company coverage: 6996.HK
Recent news on Antengene
See all newsBiotech firm Antengene's H1 revenue jumps on licensing deals
Brief: Antengene Corp Expects HY Profit Of RMB195 MLN-RMB238 MLN
Brief: Antengene Corp Receives Initial $60 Million Upfront Payment From UCB
Brief: Antengene Corp Intends To Repurchase Up To 67.92 Million Shares
Brief: Antengene Corp Enters Exclusive License Agreement With K2 Therapeutics For Atg-106